Paul S. Herendeen
2016 - Valeant Pharmaceuticals International
In 2016, Paul S. Herendeen earned a total compensation of $31.4M as Executive Vice President and Chief Financial Officer at Valeant Pharmaceuticals International.
Compensation breakdown
| Bonus | $10,400,000 |
|---|---|
| Option Awards | $15,937,869 |
| Salary | $346,154 |
| Stock Awards | $4,690,500 |
| Total | $31,374,523 |
Herendeen received $15.9M in option awards, accounting for 51% of the total pay in 2016.
Herendeen also received $10.4M in bonus, $346.2K in salary and $4.7M in stock awards.
Rankings
In 2016, Paul S. Herendeen's compensation ranked 40th out of 14,075 executives tracked by ExecPay. In other words, Herendeen earned more than 99.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 40 out of 14,075 | 100th |
Division Manufacturing | 10 out of 5,489 | 100th |
Major group Chemicals And Allied Products | 5 out of 1,895 | 100th |
Industry group Drugs | 4 out of 1,538 | 100th |
Industry Pharmaceutical Preparations | 4 out of 1,176 | 100th |
Source: SEC filing on March 21, 2018.
Herendeen's colleagues
We found two more compensation records of executives who worked with Paul S. Herendeen at Valeant Pharmaceuticals International in 2016.